Niva Bupa Health Insurance reported a 93% surge in profit to INR 1.4 billion for the first quarter of fiscal year 2027. The insurer saw a 29% rise in revenue, driven by strong growth in its retail health segment. Brokerage firm Motilal Oswal has initiated coverage on the stock with a price target of INR 103.
Niva Bupa Health Insurance Company has reported a strong start to the new financial year, with its profit after tax more than doubling to INR 1.4 billion for the quarter ending June 30, 2026. This performance significantly outperformed initial estimates, which had projected a profit of around INR 985 million. The company's insurance revenue for the quarter stood at INR 22.7 billion, representing a 29% increase compared to the same period last year.
Segment Performance and Retail Growth
The company’s growth was primarily fueled by its retail health insurance segment. Gross written premium in this core category surged by 47% year-over-year, reaching INR 16.1 billion. This trend highlights the company’s ability to gain traction in the competitive health insurance market. Total gross premiums for the insurer also saw a notable rise, growing 32% to INR 21.5 billion during the quarter.
Operational Efficiency and Profitability
Profitability metrics showed improvement as the company focused on operational efficiency. The combined insurance service ratio—a key measure that tracks how much an insurer spends on claims and expenses compared to the premiums it collects—improved by 300 basis points to 100.2%. This was better than the anticipated 103.5%, indicating that Niva Bupa is getting closer to operational profitability. The insurance service result climbed to INR 1 billion, up from INR 76 million in the same quarter of the previous fiscal year. Investment income, another vital contributor to an insurer's bottom line, grew 21% to INR 2 billion.
Brokerage Outlook and Valuation
Following these results, Motilal Oswal has initiated coverage on Niva Bupa with a "Buy" rating and set a price target of INR 103. The brokerage valuation is based on 30 times the estimated earnings per share for fiscal year 2028, reflecting an adjustment for the company's transition to Ind AS accounting standards. The Return on Equity, which measures how effectively the company uses shareholder capital, improved to 3.7% from 2.1% in the first quarter of the previous year.
For investors, the key area to track moving forward will be the company’s ability to maintain this retail health growth while continuing to improve its combined ratio toward a more sustainable sub-100% level. As the health insurance sector remains highly competitive, monitoring the persistency of these high growth rates and the company’s ability to manage claim ratios in the coming quarters will be essential.